AbbVie’s schizophrenia drug from Cerevel fails two Phase 2 trialsnews2024-11-11T15:47:26+00:00November 11th, 2024|Endpoints News|
Cigna says it will not pursue a merger with Humananews2024-11-11T14:54:54+00:00November 11th, 2024|Endpoints News|
ALK-Abelló licenses ARS’ anaphylaxis nasal spray in certain markets for $145Mnews2024-11-11T12:20:00+00:00November 11th, 2024|Endpoints News|
Aurion, Alcon enter legal battle over IPO plannews2024-11-11T11:30:23+00:00November 11th, 2024|Endpoints News|
Updated: FDA approves Autolus’ CAR-T cell therapy for aggressive blood cancernews2024-11-11T08:09:09+00:00November 11th, 2024|Endpoints News|
How Trump, RFK Jr. could influence biopharma; Viking presents weight loss data; Are MASH drugs getting boxed out by GLP-1s?; and morenews2024-11-09T11:00:54+00:00November 9th, 2024|Endpoints News|
FDA action puts Chinese API manufacturer on import block listnews2024-11-08T20:09:48+00:00November 8th, 2024|Endpoints News|
Amgen and AstraZeneca share positive results in chronic rhinosinusitisnews2024-11-08T19:30:06+00:00November 8th, 2024|Endpoints News|
Eisai slashes Leqembi sales forecast by almost $100Mnews2024-11-08T18:37:28+00:00November 8th, 2024|Endpoints News|
